Drawing for D DOMPÉ

USPTO serial 79175766

D DOMPÉ

Reviewed by CopyMark Law Group

Reg. 5126199Status 708Renewal
Filing date
Status date
Registration date
Jan 24, 2017
Examiner
THOMAS, JULIE
Law office
—

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with D DOMPÉ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kristen McCallion

Kristen McCallion Fish & Richardson P.C.P.O. Box 1022Minneapolis, MN 55440UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceuticals; gelatin capsules sold empty for pharmaceuticals;] ocular pharmaceuticals; pharmaceutical products for ophthalmological use [; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases also rare; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in tissue and organ transplantation also rare; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for treating diabetes also rare; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; sanitary preparations for medical purposes; all-purpose disinfectants]ACTIVE—
041[Entertainment television news programme services in the field of pharmaceutical products and sanitary preparations for medical purposes broadcast over the internet; organizing community festivals featuring primarily pharmaceutical exhibition for medical purposes; arranging professional workshop and training courses in the field of pharmaceutical products and medicine for medical purposes; training services in the field of pharmaceutical and sanitary preparations for medical purposes; education service, namely, providing tutoring in the field of pharmaceutical and sanitary preparations for medical purposes; providing information relating to organizing community cultural activities and contests]SECTION 71 - CANCELLED—
042Conducting early evaluations in the field of new pharmaceuticals; conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology, treatment of cancer, diabetes, analgesic preparations, nerve grow factors, oncology, organ transplantation, antibiotics, respiratory diseases, bone diseases, rare diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, medical diagnostics, drug development and pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; research and development of pharmaceuticals for the treatment of cancer, diabetes, respiratory diseases, bone diseases, rare diseases, ocular disorders and diseases; research and development in the pharmaceutical and biotechnology fieldsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 24, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Feb 13, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 1, 2025INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jan 8, 2025INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Dec 18, 2024XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Dec 18, 2024XXCRGENERIC MADRID TRANSACTION CREATED—
Dec 3, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 2, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 2, 2024NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Apr 2, 2024C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Apr 1, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 24, 2023ES75TEAS SECTION 71 & 15 RECEIVED—
Jan 24, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jun 4, 2021ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Feb 12, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 13, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 25, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 25, 2017FIMPFINAL DISPOSITION PROCESSED—
Apr 24, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 24, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 18, 2016OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Nov 8, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 8, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 19, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 19, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 19, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 28, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 28, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 28, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 28, 2016ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jun 30, 2016GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 30, 2016GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 30, 2016CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 2, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 1, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 1, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 28, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 18, 2015RFNTREFUSAL PROCESSED BY IB—
Dec 1, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 1, 2015RFRRREFUSAL PROCESSED BY MPU—
Nov 26, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 25, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 14, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 10, 2015DOCKASSIGNED TO EXAMINER—
Nov 10, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 9, 2015LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Nov 7, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance